Opinion|Videos|July 12, 2024
Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned
5